Lulimac Gel contains Luliconazole 1% w/w, a topical antifungal agent indicated for the treatment of superficial fungal infections of the skin. Luliconazole belongs to the imidazole class of antifungals and exhibits broad-spectrum activity against dermatophytes, yeasts, and molds by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Lulimac Gel is primarily prescribed for conditions such as tinea corporis, tinea cruris, and tinea pedis. The gel formulation allows for effective penetration into the affected skin layers, providing rapid relief from symptoms such as itching, scaling, and inflammation. It is applied topically once daily to the affected area, usually for a duration of 2 to 4 weeks, depending on the severity and location of the infection. Lulimac Gel is generally well tolerated, with minimal adverse effects; however, some patients may experience mild local irritation, burning, or redness at the application site. It is contraindicated in individuals with known hypersensitivity to luliconazole or any excipients in the formulation. Patients should avoid contact with eyes and mucous membranes during application. Proper adherence to the prescribed regimen is essential to prevent recurrence and ensure complete eradication of the fungal infection.